Authors

Jonathan E Shaw

MD, FRACP, FRCP(UK), FAAHMS, Deputy Director (Clinical and Population Health), Baker Heart and Diabetes Institute, Vic; Professor, School of Public Health and Preventive Medicine, Monash University, Vic


Current evidence and practical guidance for the use of sodium–glucose co-transporter-2 inhibitors in type 2 diabetes

Sodium–glucose co-transporter-2 inhibitors are becoming a cornerstone of therapy for type 2 diabetes, kidney disease and heart failure.